Literature DB >> 21139642

Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity.

Christopher Dowson1, Mohammad Shamim Khan, Prokar Dasgupta, Arun Sahai.   

Abstract

Intravesical injections of botulinum toxin-A have become established as an effective therapy in the management of neurogenic and idiopathic detrusor overactivity that is refractory to treatment with anticholinergic medication. The effects of the toxin are finite and repeated injections are required to sustain the beneficial therapeutic effects. The available data suggest a reproducible and sustained improvement in symptoms as well as urodynamic parameters following repeated injections of botulinum toxin-A. The reported incidence of adverse events is low and resistance to the toxin is uncommon. The timing of repeat injections within the published data is variable, reflecting differing practise among clinicians, but is typically 6-12 months. Larger scale studies are still required to clarify the usefulness of botulinum toxin-A as a long-term treatment in the management of detrusor overactivity.

Mesh:

Substances:

Year:  2010        PMID: 21139642     DOI: 10.1038/nrurol.2010.187

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  26 in total

Review 1.  Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.

Authors:  Dirk Dressler
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

2.  Development of resistance to botulinum toxin type A in patients with torticollis.

Authors:  P Greene; S Fahn; B Diamond
Journal:  Mov Disord       Date:  1994-03       Impact factor: 10.338

3.  Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.

Authors:  Ibrahim Fathi Ghalayini; Mohammed A Al-Ghazo; Ziad Ali Elnasser
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

4.  Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.

Authors:  Apostolos Apostolidis; Thomas S Jacques; Alex Freeman; Vinay Kalsi; Roshni Popat; Gwendoline Gonzales; Soumendra N Datta; Shabnam Ghazi-Noori; Sohier Elneil; Prokar Dasgupta; Clare J Fowler
Journal:  Eur Urol       Date:  2008-03-07       Impact factor: 20.096

5.  Antibody-induced failure of botulinum toxin type B therapy in de novo patients.

Authors:  Dirk Dressler; Hans Bigalke
Journal:  Eur Neurol       Date:  2004-10-12       Impact factor: 1.710

6.  Botulinum toxin treatment of spasmodic torticollis.

Authors:  T J Anderson; J Rivest; R Stell; M J Steiger; H Cohen; P D Thompson; C D Marsden
Journal:  J R Soc Med       Date:  1992-09       Impact factor: 5.344

7.  Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance.

Authors:  M Zuber; M Sebald; N Bathien; J de Recondo; P Rondot
Journal:  Neurology       Date:  1993-09       Impact factor: 9.910

8.  Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.

Authors:  Michael Akbar; Rainer Abel; Thorsten M Seyler; Jens Bedke; Axel Haferkamp; Hans J Gerner; Klaus Möhring
Journal:  BJU Int       Date:  2007-05-26       Impact factor: 5.588

9.  Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity.

Authors:  Arun Sahai; Christopher Dowson; Mohammad Shamim Khan; Prokar Dasgupta
Journal:  Urology       Date:  2009-12-29       Impact factor: 2.649

10.  Botulinum injections for the treatment of bladder symptoms of multiple sclerosis.

Authors:  Vinay Kalsi; Gwen Gonzales; Roshni Popat; Apostolos Apostolidis; Sohier Elneil; Prokar Dasgupta; Clare J Fowler
Journal:  Ann Neurol       Date:  2007-11       Impact factor: 10.422

View more
  9 in total

1.  Repeated botulinum toxin type A (Dysport) injections for women with intractable detrusor overactivity: a prospective outcome study.

Authors:  Lanka Abeywickrama; Angamuthu Arunkalaivanan; Monica Quinlan
Journal:  Int Urogynecol J       Date:  2013-10-17       Impact factor: 2.894

Review 2.  OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury.

Authors:  Mark Sanford
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

3.  Botulinum toxin A should not be first-line therapy for overactive bladder.

Authors:  Lesley K Carr
Journal:  Can Urol Assoc J       Date:  2011-06       Impact factor: 1.862

4.  Moving beyond ineffective medication for OAB.

Authors:  Stephen S Steele
Journal:  Can Urol Assoc J       Date:  2011-06       Impact factor: 1.862

5.  Botulinum toxin A: First-line therapy for idiopathic detrusor overactivity.

Authors:  Stephen S Steele
Journal:  Can Urol Assoc J       Date:  2011-06       Impact factor: 1.862

Review 6.  Highlights of the university of toronto urology update 2014.

Authors:  Sender Herschorn
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

Review 7.  Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management.

Authors:  Arun Sahai; Eduardo Cortes; Jai Seth; Muhammad Shamim Khan; Jalesh Panicker; Cornelius Kelleher; Thomas M Kessler; Clare J Fowler; Prokar Dasgupta
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

8.  Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.

Authors:  Ann T Hanna-Mitchell; Amanda S Wolf-Johnston; Stacey R Barrick; Anthony J Kanai; Michael B Chancellor; William C de Groat; Lori A Birder
Journal:  Neurourol Urodyn       Date:  2013-10-26       Impact factor: 2.696

9.  Onabotulinum toxin a (botox®) in the treatment of neurogenic bladder overactivity.

Authors:  Malene Rohrsted; Cecilie Bagi Nordsten; Per Bagi
Journal:  Nephrourol Mon       Date:  2012-03-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.